Identifying Care Challenges as Opportunities for Research and Education in Inflammatory Bowel Disease in South Asia.

[1]  T. Shim,et al.  The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea , 2022, Journal of Korean medical science.

[2]  S. Sebastian,et al.  Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance. , 2021, The lancet. Gastroenterology & hepatology.

[3]  D. Lad,et al.  TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India , 2021, BMC Gastroenterology.

[4]  P. Irving,et al.  P241 Gastrointestinal ultrasound instead of magnetic resonance enterography: Large potential cost savings with limited clinical downsides , 2021 .

[5]  P. Pal,et al.  Sa517 HIGH PREVALENCE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE IN INDIAN IBD PATIENTS IRRESPECTIVE OF EDUCATIONAL AND SOCIOECONOMIC STATUS: ITS THE PERCEPTION OF SAFETY THAT MATTERS! , 2021 .

[6]  Mayank Jain,et al.  Inflammatory bowel disease: An Indian perspective , 2021, The Indian journal of medical research.

[7]  N. Bansal,et al.  Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study , 2021, Intestinal research.

[8]  A. Dang,et al.  Importance of Evidence-Based Health Insurance Reimbursement and Health Technology Assessment for achieving Universal Health Coverage and Improved Access to Health in India. , 2021, Value in health regional issues.

[9]  A. Griffiths,et al.  STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. , 2020, Gastroenterology.

[10]  A. Sood,et al.  Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry , 2020, Intestinal research.

[11]  Vishal Sharma.  Differentiating intestinal tuberculosis and Crohn disease: Quo Vadis , 2020, Expert review of gastroenterology & hepatology.

[12]  A. Roslani,et al.  Low Acceptance of Surgery Results in High Morbidity and Mortality Among Asian Patients With IBD , 2020, Diseases of the colon and rectum.

[13]  T. H. Nguyen,et al.  The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2019, The lancet. Gastroenterology & hepatology.

[14]  P. Pal,et al.  Risk factors for diagnostic delay in Crohn's disease and their impact on long‐term complications: how do they differ in a tuberculosis endemic region? , 2018, Alimentary pharmacology & therapeutics.

[15]  A. Kamath,et al.  Cost of Illness in Inflammatory Bowel Disease , 2017, Digestive Diseases and Sciences.

[16]  C. von Wagner,et al.  Understanding low colorectal cancer screening uptake in South Asian faith communities in England – a qualitative study , 2015, BMC Public Health.

[17]  S. Srivastava,et al.  Clinical, Endoscopic, and Histological Differentiations Between Crohn's Disease and Intestinal Tuberculosis , 2010, The American Journal of Gastroenterology.

[18]  W. El-Sadr,et al.  Sensitivity Analysis and Potential Uses of a Novel Gamma Interferon Release Assay for Diagnosis of Tuberculosis , 2006, Journal of Clinical Microbiology.